Same-Day Carotid Artery Stenting and Coronary Artery Bypass Surgery.
Coronary disease
Lyme carditis
carotid artery stenting
carotid disease
complete heart block
coronary artery bypass grafting surgery
right bundle branch block
Journal
Texas Heart Institute journal
ISSN: 1526-6702
Titre abrégé: Tex Heart Inst J
Pays: United States
ID NLM: 8214622
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
entrez:
3
2
2023
pubmed:
4
2
2023
medline:
8
2
2023
Statut:
ppublish
Résumé
The optimal treatment strategy for patients with severe carotid artery disease undergoing coronary artery bypass grafting is still problematic. The important question is whether it is necessary to treat significant carotid disease in patients who have undergone coronary artery bypass grafting. This study analyzed short- and midterm results after same-day carotid artery stenting and coronary artery bypass grafting. From 2013 to 2020, a total of 69 patients were enrolled in the study. Same-day carotid artery stenting and coronary artery bypass grafting were performed in all patients. The study's primary end points were the evaluation rate of stroke, myocardial infarction, and death within short- and midterm periods after the procedures. The 30-day mortality was 0%. The occurrences of perioperative adverse events, namely stroke, myocardial infarction, and transient ischemic attack, were 1 (1.4%), 1 (1.4%), and 4 (5.8%), respectively. Mean (IQR) follow-up time was 28 (IQR, 17-43) months. Six (8.8%) patients died during this period. Fatal stroke was registered in 2 cases, and 1 patient experienced a disabling stroke with a fatal outcome. The other 3 patients died because of chronic renal disease, a traffic accident, and for an unknown reason, respectively. Midterm survival in the group was 91.2%. The study showed that same-day carotid artery stenting and coronary artery bypass grafting for concomitant carotid and coronary disease treatment could be a promising and feasible therapeutic strategy.
Sections du résumé
BACKGROUND
The optimal treatment strategy for patients with severe carotid artery disease undergoing coronary artery bypass grafting is still problematic. The important question is whether it is necessary to treat significant carotid disease in patients who have undergone coronary artery bypass grafting. This study analyzed short- and midterm results after same-day carotid artery stenting and coronary artery bypass grafting.
METHODS
From 2013 to 2020, a total of 69 patients were enrolled in the study. Same-day carotid artery stenting and coronary artery bypass grafting were performed in all patients. The study's primary end points were the evaluation rate of stroke, myocardial infarction, and death within short- and midterm periods after the procedures.
RESULTS
The 30-day mortality was 0%. The occurrences of perioperative adverse events, namely stroke, myocardial infarction, and transient ischemic attack, were 1 (1.4%), 1 (1.4%), and 4 (5.8%), respectively. Mean (IQR) follow-up time was 28 (IQR, 17-43) months. Six (8.8%) patients died during this period. Fatal stroke was registered in 2 cases, and 1 patient experienced a disabling stroke with a fatal outcome. The other 3 patients died because of chronic renal disease, a traffic accident, and for an unknown reason, respectively. Midterm survival in the group was 91.2%.
CONCLUSION
The study showed that same-day carotid artery stenting and coronary artery bypass grafting for concomitant carotid and coronary disease treatment could be a promising and feasible therapeutic strategy.
Identifiants
pubmed: 36735614
pii: 490544
doi: 10.14503/THIJ-21-7781
pmc: PMC9969787
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 by the Texas Heart® Institute, Houston.
Références
Eur Heart J. 2018 Mar 1;39(9):763-816
pubmed: 28886620
Eur J Vasc Endovasc Surg. 2011 May;41(5):607-24
pubmed: 21396854
Circulation. 2007 Oct 30;116(18):2036-42
pubmed: 17938290
J Vasc Surg. 2013 Feb;57(2 Suppl):58S-63S
pubmed: 23336857
BMJ Open. 2017 Oct 06;7(10):e017823
pubmed: 28988183
J Am Coll Cardiol. 2013 Nov 19;62(21):1948-1956
pubmed: 23876675
Ann Thorac Surg. 2014 Jan;97(1):102-9
pubmed: 24090581
JACC Cardiovasc Interv. 2009 May;2(5):393-401
pubmed: 19463460
N Engl J Med. 2016 Mar 17;374(11):1011-20
pubmed: 26886419
Catheter Cardiovasc Interv. 2018 Feb 15;91(S1):632-638
pubmed: 29356307
Ann Thorac Surg. 2015 Apr;99(4):1291-7
pubmed: 25661578
Eur J Vasc Endovasc Surg. 2018 Nov;56(5):741-748
pubmed: 30197287
Ann Thorac Surg. 2020 Nov;110(5):1557-1563
pubmed: 32247782
Eur J Vasc Endovasc Surg. 2009 Nov;38(5):556-9
pubmed: 19716714
Ann Thorac Surg. 2007 Apr;83(4):1389-95
pubmed: 17383345
J Vasc Surg. 2011 May;53(5):1237-41
pubmed: 21247729
Stroke. 2017 Oct;48(10):2769-2775
pubmed: 28916664
Catheter Cardiovasc Interv. 2019 Feb 15;93(3):E134-E139
pubmed: 30411845
JACC Cardiovasc Interv. 2017 Feb 13;10(3):286-298
pubmed: 28183469
N Engl J Med. 2008 Apr 10;358(15):1572-9
pubmed: 18403765
J Am Coll Cardiol. 2017 May 9;69(18):2266-2275
pubmed: 28473130
Stroke. 2017 Oct;48(10):2650-2651
pubmed: 28916669
Eur J Vasc Endovasc Surg. 2011 Sep;42 Suppl 1:S73-83
pubmed: 21855029
J Am Coll Cardiol. 2011 Feb 22;57(8):1002-44
pubmed: 21288680
Eur J Vasc Endovasc Surg. 2009 Apr;37(4):379-87
pubmed: 19201215
Ann Thorac Surg. 2004 Nov;78(5):1564-71
pubmed: 15511432
Ann Vasc Surg. 2020 Jan;62:463-473.e4
pubmed: 31449948